Among these, the seven most frequent fusion partners—MLLT3 (30%), MLLT10 (19%), ELL (10%), AFDN (8%), MLLT1 (4%), EPS15 (1%), AFF1 (1%), and partial tandem duplication (10%)—account for approximately 80% of KMT2A recombination events in AML [1]. The gene discussed is MLLT3; the disease is acute myeloid leukemia.